158 Overcoming Docetaxel Resistance in Prostate Cancer by Targeting FAK Phosphorylation, and Its Mode of Action von Lee, B.Y, Hochgräfe, F, Lin, H.M, Castillo, L, Raftery, M, Horvath, L.G, Daly, R.J

Volltext

The evolution of chemotherapy for the treatment of prostate cancer von Quinn, D.I., Sandler, H.M., Horvath, L.G., Goldkorn, A., Eastham, J.A.

Volltext

Statins – No more cream for cancer von Gillessen, S., Horvath, L.G.

Volltext

1618P Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304) von Hamid, A.A., Thomas, H., Martin, A., Soon, Y.Y., Horvath, L.G., Zielinski, R., Thomson, A., Tan, H., Sandhu, S.K., Reaume, M.N., Pook, D.W., Parnis, F., McDermott, R.S., Lawrence, N., Frydenberg, M., Chi, K.N., Stockler, M.R., Davis, I.D., Sweeney, C.

Volltext

1607P Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304) von Horvath, L.G., Lin, H-M., Davis, I.D., Martin, A., Scheinberg, T., Meikle, P., Joshua, A., Mcjannett, M., Subhash, V., Yip, S., North, S., McDermott, R.S., Chi, K.N., Stockler, M.R., Sweeney, C.

Volltext

1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with L... von Tolmeijer, S.H., Kwan, E.M., Ng, S.W.S., Joshua, A., Emmett, L., Crumbaker, M., Hamid, A.A., Anton, A., Horvath, L.G., Chan, J., Bressel, M., Buteau, J.P., Dhiantravan, N., Ayati, N., Keerthikumar, S., Goode, D., Hicks, R., Hofman, M.S., Wyatt, A.W., Sandhu, S.K.

Volltext

1409P Development of a clinically accessible, circulating prognostic lipid biomarker panel in men with mCRPC to guide potential metabolic intervention von Scheinberg, T., Fitzpatrick, M., Lin, H-M., Azad, A.A., Bonnitcha, P., Davies, A.G., Heller, G., Huynh, K., Mak, B., Mahon, K., Meikle, P., Sullivan, D., Horvath, L.G.

Volltext

1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304) von Horvath, L.G., Davis, I.D., Martin, A., Zielinski, R., Thomson, A., Tan, T.H., Sandhu, S.K., Reaume, M.N., Pook, D., Parnis, F., North, S., Marx, G.M., McCaffrey, J.A., McDermott, R.S., Lawrence, N., Frydenberg, M., Chowdhury, S., Chi, K.N.N., Stockler, M.R., Sweeney, C.

Volltext

1831P Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism? von Horvath, L.G., Kench, C., Mellor, R., Lin, H-M., Mak, B., Scheinberg, T., Mahon, K., Graham, L., Azad, A.A., Joshua, A.M., Stockler, M.R., Marx, G.M., Briscoe, K., Samaras, K.

Volltext

586P Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASC... von Day, D., Starus, A., Gebski, V., Simes, J., Hayes, T., Padinharakam, S., Strickland, A.H., Briscoe, K., Varma, S., Barnet, M., Jackson, C., Horvath, L.G., Price, T.J., Tebbutt, N., Karki, B., Diakos, C.I., Chia, J., Toh, H.C., Jones, F.S., Segelov, E.

Volltext

1610P Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig von Armstrong, A.J., Appleman, L.J., Danila, D.C., Lin, C-C., Lee, J.L., Matsubara, N., Ward, P.J., Pook, D.W., Kim, M., Dorff, T.B., Fischer, S.C., Lin, Y-C., Horvath, L.G., Sumey, C., Yang, Z., Decato, B.E., Englert, J.M., Smith, K.M., Lolkema, M., Kelly, W.K.

Volltext

1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohor... von Kelly, W.K., Appleman, L.J., Lin, C-C., Armstrong, A.J., Fischer, S.C., Pook, D.W., Perez Gracia, J.L., Lee, J.L., Berthold, D.R., Ward, P.J., Castellano Gauna, D.E., Horvath, L.G., Kim, M., Matsubara, N., Sumey, C., Shabooti, M., Yang, Z., Connarn, J., Stieglmaier, J., Danila, D.C.

Volltext

1727MO Can proteomics predict metastatic relapse in leiomyosarcoma (LMS)? Development of an 8 protein signature in a >350 sample study including a validation cohort von Connolly, E.A., Bucio-Noble, D., Cai, S., Singh, A., Koh, J., Karim, R., Lazar, A., Lim, R., Morey, R., Ratnayake, G., Hains, P., Ye, L., Ingram, D., Scott, C.L., Robinson, P.J., Barker, H., Nassif Haddad, E.F., Horvath, L.G., Grimison, P., Reddel, R.

Volltext

318MO Circulating tumour DNA (ctDNA) dynamics, CEA and sites of recurrence for the randomised DYNAMIC study: Adjuvant chemotherapy (ACT) guided by ctDNA analysis in stage II colon... von Tie, J., Cohen, J., Lahouel, K., Lo, S.N., Wang, Y., Wong, R., Shapiro, J., Harris, S., Khattak, A., Burge, M., Horvath, L.G., Karapetis, C.S., Shannon, J., Singh, M., Yip, D., Papadopoulos, N., Tomasetti, C., Kinzler, K., Vogelstein, B., Gibbs, P.

Volltext

1713P Single-cell transcriptomic analysis of appendiceal cancer peritoneal disease von Strach, M.C., Yeung, N., Apostolov, E., Lin, H-M., Nagaraju, R.T., Ansari, N., Koh, C., Shin, J-S., Kench, J., Aziz, O., Swarbrick, A., Horvath, L.G., Barriuso, J., Mahon, K.

Volltext

Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer von Hulf, T, Sibbritt, T, Wiklund, E D, Patterson, K, Song, J Z, Stirzaker, C, Qu, W, Nair, S, Horvath, L G, Armstrong, N J, Kench, J G, Sutherland, R L, Clark, S J

Volltext

264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) von Kelly, W.K., Danila, D.C., Lin, C-C., Lee, J-L., Matsubara, N., Ward, P.J., Armstrong, A.J., Pook, D.W., Kim, M., Dorff, T., Fischer, S., Lin, Y-C., Horvath, L.G., Sumey, C., Yang, Z., Jurida, G., Connarn, J., Penny, H., Stieglmaier, J., Appleman, L.J.

Volltext

1765O Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC... von Kelly, W., Danila, D., Lin, C-C., Lee, J-L., Matsubara, N., Ward, P., Armstrong, A.J., Pook, D., Kim, M., Dorff, T., Fischer, S., Lin, Y-C., Horvath, L.G., Sumey, C., Yang, Z., Jurida, G., Connarn, J., Penny, H., Stieglmaier, J., Appleman, L.J.

Volltext

596P Impact of combined lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) von Mak, B., Lin, H-M., Kwan, E.M., Fettke, H., Tran, B., Davis, I.D., Mahon, K.L., Stockler, M.R., Briscoe, K., Marx, G.M., Kohli, M., Tan, W., Huynh, K., Du, P., Yu, J., Jia, S., Joshua, A.M., Azad, A.A., Meikle, P.J., Horvath, L.G.

Volltext

577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC) von Sandhu, S.K., Joshua, A.M., Emmett, L., Spain, L., Horvath, L.G., Crumbaker, M., Anton, A., Wallace, R., Pasam, A., Bressel, M., Cassidy, E., Banks, P., Kumar, A.R., Alipour, R., Akhurst, T., Kong, G., Davis, I.D., Williams, S., Hicks, R., Hofman, M.

Volltext